benserazide has been researched along with Syndrome in 8 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Syndrome: A characteristic symptom complex.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A quantitative evaluation of cerebellar ataxia, with an ataxia score (total, static, kinetic) and the measurement of objective values relating to the major symptoms, was used in 21 patients with hereditary ataxias treated for 12 months with high doses (16 mg/kg/day) of d-l-5-HTP, l-5-HTP or the combination d-l-5-HTP (16 mg/kg/day)--benserazide (6 mg/kg/day)." | 7.67 | Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide. ( Trouillas, P, 1984) |
| "A quantitative evaluation of cerebellar ataxia, with an ataxia score (total, static, kinetic) and the measurement of objective values relating to the major symptoms, was used in 21 patients with hereditary ataxias treated for 12 months with high doses (16 mg/kg/day) of d-l-5-HTP, l-5-HTP or the combination d-l-5-HTP (16 mg/kg/day)--benserazide (6 mg/kg/day)." | 3.67 | Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide. ( Trouillas, P, 1984) |
| "Psychotic features in patients with Parkinson's Disease usually present as visual hallucinations against a background of cognitive deterioration and dopaminomimetic therapy." | 1.36 | Isolated delusional syndrome in Parkinson's Disease. ( Bozi, M; Christodoulou, C; Douzenis, A; Gasparinatos, G; Stamboulis, E; Stefanis, C; Stefanis, L; Stefanis, N, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stefanis, N | 1 |
| Bozi, M | 1 |
| Christodoulou, C | 1 |
| Douzenis, A | 1 |
| Gasparinatos, G | 1 |
| Stamboulis, E | 1 |
| Stefanis, C | 1 |
| Stefanis, L | 1 |
| Lian, XF | 1 |
| Luo, XD | 1 |
| Zweije-Hofman, IL | 1 |
| van der Zee, HJ | 1 |
| van Nieuwenhuizen, O | 1 |
| Trouillas, P | 1 |
| Atchison, PR | 1 |
| Thompson, PD | 1 |
| Frackowiak, RS | 1 |
| Marsden, CD | 1 |
| Massarotti, G | 1 |
| Cassi, E | 1 |
| Passaleva, A | 1 |
| De Keyser, J | 1 |
| Herroelen, L | 1 |
| Vervaeck, M | 1 |
| Bruyland, M | 1 |
| Ebinger, G | 1 |
| Görke, W | 1 |
| Bartholomé, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Influence of Sensory Stimuli on Gait Imagery in Patients With Freezing of Gait[NCT01071590] | 45 participants (Actual) | Observational | 2010-02-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for benserazide and Syndrome
| Article | Year |
|---|---|
The syndrome of gait ignition failure: a report of six cases.
Topics: Aged; Benserazide; Brain; Carbidopa; Diagnosis, Differential; Drug Therapy, Combination; Female; Gai | 1993 |
2 trials available for benserazide and Syndrome
| Article | Year |
|---|---|
[Effect of TCM treatment according to syndrome differentiation in enhancing curative effect and reducing side-effect of madopa].
Topics: Aged; Aged, 80 and over; Benserazide; Diagnosis, Differential; Dopamine Agents; Drug Combinations; D | 2007 |
Anti-parkinson drugs in the Batten-Spielmeyer-Vogt syndrome; a pilot trial.
Topics: Adolescent; Adult; Amantadine; Antiparkinson Agents; Benserazide; Drug Combinations; Humans; Levodop | 1982 |
5 other studies available for benserazide and Syndrome
| Article | Year |
|---|---|
Isolated delusional syndrome in Parkinson's Disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Benserazide; Benzothiazoles; Catechols; Clonazepam; Female; | 2010 |
Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide.
Topics: 5-Hydroxytryptophan; Benserazide; Cerebellar Ataxia; Dopamine; Drug Therapy, Combination; Friedreich | 1984 |
Lupus-like autoimmune syndrome after levodopa and benserazide.
Topics: Autoimmune Diseases; Benserazide; Humans; Hydrazines; Levodopa; Lupus Erythematosus, Systemic; Male; | 1979 |
Idiopathic hemiparetic parkinsonism, a syndrome distinct from idiopathic parkinsonism.
Topics: Adult; Benserazide; Drug Combinations; Female; Hemiplegia; Humans; Levodopa; Parkinson Disease; Post | 1992 |
Biochemical and neurophysiological investigations in two forms of Segawa's disease.
Topics: Adolescent; Basal Ganglia Diseases; Benserazide; Diagnosis, Differential; Dystonia; Evoked Potential | 1990 |